tirzepatide otc / Niacinamide Injection 1 and GIP mechanism in a daily Tirzepatide for Weight Loss |

Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]

The branded retail prices ($1,000+/month) are a separate problem driven by US drug pricing policy and aren't the question here

The Takeaway GLP-1 drugs like Ozempic and Mounjaro show promising benefits for people with type 1 diabetes, including weight loss and improved blood sugar levels, but they carry significant risks

Physical dependency is one characteristic of addiction

You can potentially add morning application during winter without the UV exposure concerns present in summer